Established in 2010, Oncotarget has grown to become one of the biggest and notable bio medical journals in the world. Published by Impact Journals, the twice weekly journals combine an array of medical research and oncology related literary content for readers. Follow Oncotarget on Twitter.
The group conducted one of the largest medical related summits in 2015. Medical professionals, researchers and students gathered in London. U.K to discuss the biology of aging. The summit provided a platform for professionals to share their extensive knowledge as well as discuss a host of ideas amongst their peers. Taking place in February of 2015, the information gathered that day has helped propel the research put into the field of cell aging. Follow Oncotarget on Linkedin.
The summit was split into four major sections, allowing guest to gather their thoughts and provide well receptive feedback. The aging of the brain, slowing down progression, self repair and age related diseases were the major key speaking points at the summit.
Following the previous success of their summit, the team at Oncotarget has recently dominated medical headlines for another possible medical breakthrough publishing. The group produced combined hours of research and presented the results of a Harvard Medical School team and its possible therapeutic strategy to treat drug resistant strands of thyroid cancer.
The results concluded that a FDA approved drug used formally to treat breast cancer, Palbociclib may be able to withstand resistance. Once coupled with Vemurafenib, the combination works effectively to prevent reoccurring cancer cells from splitting and mutating. Together the drugs also induce a stronger cell death rate than each could do on its own separately.
As the treatment is tested in clinical trials, studies further support the therapeutic strategy of both drugs used together for thyroid cancer treatment. By assisting in eliminating existing cancer cells and the prevention of possible new mutated cells from forming, patients are able to increase their chances of survival against the specifically targeted thyroid cancer.